Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System AtrophyGlobeNewsWire • 07/17/24
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System AtrophyGlobeNewsWire • 07/17/24
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' WebinarGlobeNewsWire • 06/12/24
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History StudyGlobeNewsWire • 05/29/24
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third ReviewGlobeNewsWire • 05/08/24
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's AtaxiaGlobeNewsWire • 04/29/24
Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual MeetingGlobeNewsWire • 04/17/24
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024GlobeNewsWire • 04/10/24
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive RefundGlobeNewsWire • 03/26/24
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingGlobeNewsWire • 02/20/24
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second ReviewGlobeNewsWire • 02/06/24
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This WeekGlobeNewsWire • 01/29/24
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesGlobeNewsWire • 01/22/24
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical ProgressGlobeNewsWire • 12/04/23
Biotech Alterity Jumps On Upbeat Parkinson's Treatment Clinical Trial DataInvestors Business Daily • 12/04/23
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's DiseaseGlobeNewsWire • 12/04/23
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System AtrophyGlobeNewsWire • 11/27/23
Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434GlobeNewsWire • 11/16/23